基本情報
- CAS
1722-62-9- 標準SMILES
Cc1cccc(C)c1NC(=O)C1CCCCN1C.Cl- InChIKey
RETIMRUQNCDCQB-UHFFFAOYSA-N- 分子式
- C15H23ClN2O
- 平均分子量
- 282.81 g/mol
- 単同位体質量
- 282.14989104
概要
Mepivacaine hydrochloride is the hydrochloride salt of mepivacaine. It is used as a local anaesthetic. It has a role as a local anaesthetic. It is a hydrochloride and a piperidinecarboxamide. It is functionally related to a mepivacaine.
名称と識別子
- 優先名称
- Mepivacaine Hydrochloride
- IUPAC
- N-(2,6-dimethylphenyl)-1-methylpiperidine-2-carboxamide;hydrochloride
- 現地名
- メピバカイン塩酸塩
- 英語名
- Mepivacaine hydrochloride
- 分子式
- C15H22N2O.ClH
- 分子量
- 282.81
名称と別名
Mepivacaine hydrochloride1722-62-9Mepivacaine HCLScandicainOptocainScandonest PlainPolocaine-MpfArestocaine hydrochlorideMepivacaine MonohydrochlorideISOCAINE HYDROCHLORIDE1-Methyl-2',6'-pipecoloxylidide hydrochloride1-Methyl-2',6'-pipecoloxylidide monohydrochloride
名称をさらに表示
N-(2,6-ジメチルフェニル)-1-メチル-2-ピペリジンカルボアミド·塩酸塩メピバカイン塩酸塩塩酸メピバカインカルボカイン塩酸塩塩酸メピパカインN-(2,6-ジメチルフェニル)-1-メチル-2-ピペリジンカルボキサミド塩酸塩メピバカイン 塩酸塩メピバカイン塩酸塩 (JP17)N-(2,6-Dimethylphenyl)-1-methylpiperidine-2-carboxamide hydrochlorideMepivacaine ImpurityMeaverinMepidentMepicatonChlorocainCarbocainaScandonest
4VFX2L7EM5NSC-758674(1-Methyl-DL-piperidine-2-carboxylic acid)-2,6-dimethylanilide hydrochlorideCHEBI:67602-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, hydrochloride (1:1)N-(2,6-dimethylphenyl)-1-methylpiperidine-2-carboxamide hydrochloride (1:1)Iq Dental MepivacaineScandonest 3% Plain
物性
構造計算による物性
- 極性表面積
- 32.3 Ų
- 水素結合供与体数
- 2
- 水素結合受容体数
- 2
- 回転可能結合数
- 2
- 重原子数
- 19
- 形式電荷
- 0
- 複雑度
- 282
実験および物理化学的性質
Solubility>42.4 [ug/mL] (The mean of the results at pH 7.4)
Human Drugs
Breast Feeding; Lactation; Anesthetics, Local
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Animal Drugs
Active Ingredients (Mepivacaine Hydrochloride) -> FDA Greenbook
Pharmaceuticals -> UK Veterinary Medicines Directorate List
Collision Cross Section157.6 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
物理化学的性質
- 融点
- 255 · 255-257°C (dec.)
- 貯蔵温度
- 2 · 2-8°C
- 溶解性
- 2 O: · H2O: 可溶20mg/mL、透明
- 外見
- 粉
- 色
- 白からベージュ
- 水溶解度
- 2 O: · H2O: 20mg/mL, clear
- InChI
- InChI=1S/C15H22N2O.ClH/c1-11-7-6-8-12(2)14(11)16-15(18)13-9-4-5-10-17(13)3;/h6-8,13H,4-5,9-10H2,1-3H3,(H,16,18);1H
- InChIKey
- RETIMRUQNCDCQB-UHFFFAOYSA-N
- SMILES
- C1(=C(C)C=CC=C1C)NC(=O)C1CCCCN1C.Cl
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
GHS分類
GHS Classification
Danger
H301 (66.1%): Toxic if swallowed [Danger Acute toxicity, oral]
P264, P270, P273, P301+P316, P301+P317, P321, P330, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 62 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Danger
H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]
危険有害性情報
Regulatory InformationMepivacaine hydrochloride: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Other Safety InformationIMAP assessments - 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, monohydrochloride: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 3 (66.1%)
毒性情報
Treatment
Treatment of a patient with toxic manifestations consists of assuring and maintaining a patient airway and supporting ventilation (respiration) as required. This usually will be sufficient in the management of most reactions. Should a convulsion persist despite ventilatory therapy, small increments of anticonvulsive agents may be given intravenously, such as benzodiazephine (e.g., diazepam) or ultrashort-acting barbiturates (e.g., thiopental or thiamylal) or short-acting barbiturates (e.g., pentobarbital or secobarbital). Cardiovascular depression may require circulatory assistance with intravenous fluids and/or vasopressor (e.g., Ephedrine) as dictated by the clinical situation. (L1712)
Exposure Routes
化学と産業
薬理情報
Metabolism/Metabolites
Rapidly metabolized, with only a small percentage of the anesthetic (5 percent to 10 percent) being excreted unchanged in the urine. The liver is the principal site of metabolism, with over 50% of the administered dose being excreted into the bile as metabolites. Route of Elimination: It is rapidly metabolized, with only a small percentage of the anesthetic (5 percent to 10 percent) being excreted unchanged in the urine.The liver is the principal site of metabolism, with over 50% of the administered dose being excreted into the bile as metabolites. Half Life: The half-life of mepivacaine in adults is 1.9 to 3.2 hours and in neonates 8.7 to 9 hours.
FDA Pharmacological Classification
MEPIVACAINE HYDROCHLORIDE
Amides [CS]; Amide Local Anesthetic [EPC]; Local Anesthesia [PE]
POLOCAINE (MEPIVACAINE HCL)
Amide Local Anesthetic [EPC]; Amides [CS]; Local Anesthesia [PE]
MeSH Pharmacological Classification
Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate.
用途と製造
UsesFor production of local or regional analgesia and anesthesia by local infiltration, peripheral nerve block techniques, and central neural techniques including epidural and caudal blocks.
Use ClassificationAnimal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients
General Manufacturing Information
関連反応
2 件
化合物ノート
読み込み中…